StockData
AnaptysBio, Inc logo

AnaptysBio, Inc (ANAB) stock

ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30
$49.24+2.63 (+5.64%)

Close on Oct 19, 2026Market cap $2.28BP/E –Yield –

AnaptysBio net income

Net income is the profit left for shareholders after every expense, interest and tax.

AnaptysBio's net income for the twelve months ending Jun 30, 2026 was $195.72M. For fiscal 2025 it was -$13.23M. The highest annual figure on record is -$4.26M in fiscal 2016.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$13.23M–
FY2024Dec 31, 2024-$145.23M–
FY2023Dec 31, 2023-$163.62M–
FY2022Dec 31, 2022-$128.72M–
FY2021Dec 31, 2021-$57.80M–
FY2020Dec 31, 2020-$19.93M–
FY2019Dec 31, 2019-$97.34M–
FY2018Dec 31, 2018-$61.66M–
FY2017Dec 31, 2017-$30.07M–
FY2016Dec 31, 2016-$4.26M–
FY2015Dec 31, 2015-$5.41M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$183.88M–
Q1 FY2026Mar 31, 2026-$52.88M–
Q4 FY2025Dec 31, 2025$49.61M–
Q3 FY2025Sep 30, 2025$15.11M–
Q2 FY2025Jun 30, 2025-$38.63M–
Q1 FY2025Mar 31, 2025-$39.33M–
Q4 FY2024Dec 31, 2024-$21.78M–
Q3 FY2024Sep 30, 2024-$32.85M–
Q2 FY2024Jun 30, 2024-$46.66M–
Q1 FY2024Mar 31, 2024-$43.94M–
Q4 FY2023Dec 31, 2023-$42.21M–
Q3 FY2023Sep 30, 2023-$37.31M–
Q2 FY2023Jun 30, 2023-$39.85M–
Q1 FY2023Mar 31, 2023-$44.26M–
Q4 FY2022Dec 31, 2022-$26.41M–
Q3 FY2022Sep 30, 2022-$33.50M–
Q2 FY2022Jun 30, 2022-$32.55M–
Q1 FY2022Mar 31, 2022-$36.26M–
Q4 FY2021Dec 31, 2021-$32.54M-196.7%
Q3 FY2021Sep 30, 2021-$6.67M–
Q2 FY2021Jun 30, 2021-$429.00K–
Q1 FY2021Mar 31, 2021-$18.16M–
Q4 FY2020Dec 31, 2020$33.65M–
Q3 FY2020Sep 30, 2020-$23.77M–
Q2 FY2020Jun 30, 2020-$21.55M–
Q1 FY2020Mar 31, 2020-$8.26M–
Q4 FY2019Dec 31, 2019-$20.26M–
Q3 FY2019Sep 30, 2019-$31.03M–
Q2 FY2019Jun 30, 2019-$23.96M–
Q1 FY2019Mar 31, 2019-$22.08M–
Q4 FY2018Dec 31, 2018-$16.99M–
Q3 FY2018Sep 30, 2018-$15.96M–
Q2 FY2018Jun 30, 2018-$13.62M–
Q1 FY2018Mar 31, 2018-$15.09M–
Q4 FY2017Dec 31, 2017-$6.86M–
Q3 FY2017Sep 30, 2017-$9.09M–
Q2 FY2017Jun 30, 2017-$2.68M–
Q1 FY2017Mar 31, 2017-$11.44M–
Q4 FY2016Dec 31, 2016-$4.58M–
Q3 FY2016Sep 30, 2016-$1.12M–

More AnaptysBio figures

See a number that looks wrong?